You are here

Vascepa

FDA approves the first generic for Amarin's Vascepa — but is a launch imminent?

Endpoints

Fri, 05/22/20 - 11:03 am

Can Amarin's Stock Recover From Its 70% Implosion?

Motley Fool

Sat, 04/18/20 - 11:24 pm

Are Amarin's Blockbuster Dreams Over?

Motley Fool

Sun, 04/5/20 - 02:37 pm

Disaster at Amarin: Stock plummets 70% after Vascepa patent challenge loss

Fierce Pharma

Mon, 03/30/20 - 08:20 pm

Amarin aims for Vascepa boom with doubled sales force nearly in place

Fierce Pharma

Wed, 02/26/20 - 11:31 pm

With Vascepa nod in the bag, Amarin rolls CV risk campaign targeting passé prescription meds

Fierce Pharma

Thu, 01/23/20 - 12:33 pm

JPM: With Vascepa's U.S. expansion rolling, Amarin CEO holds off partner offers in EU

Fierce Pharma

Thu, 01/16/20 - 11:06 pm

AstraZeneca's Epanova flunks key heart risk trial, giving Amarin's rival Vascepa a leg up

Fierce Pharma

Mon, 01/13/20 - 11:01 am

clinical trials

Vascepa sparkle set to light up Amarin's fourth quarter revenue

Endpoints

Tue, 01/7/20 - 10:31 am

Amarin stock heads toward highest prices in more than a decade after new Vascepa FDA approval

Yahoo/Marketwatch

Sun, 12/15/19 - 11:20 pm

Amarin eyes blockbuster Vascepa sales as FDA grants heart-helping label expansion

Fierce Pharma

Fri, 12/13/19 - 09:36 pm

2 Top Biotech Buyout Candidates

Motley Fool

Wed, 12/11/19 - 10:38 am

Aurinia Pharmaceuticals

3 Biotechs Facing FDA Approvals by Year's End

Motley Fool

Mon, 12/9/19 - 09:45 am

Intra-Cellular Therapies

4 FDA Dates Biotech Investors Should Circle in December

Motley Fool

Sun, 12/8/19 - 10:24 pm

anti-inflammatories

Bausch Health Companies

Intra-Cellular Therapies

Go or no go? Vascepa’s finale and Allergan's pain relief

EP Vantage

Mon, 12/2/19 - 10:37 am

Before 2019 closes, the FDA has 3 key approval decisions to make

Biopharma Dive

Wed, 11/27/19 - 12:43 pm

Intra-Cellular Therapeutics

bipolar disorder

Does Amarin Have a Dark Horse Suitor?

Motley Fool

Sun, 11/24/19 - 11:32 pm

Gilead Sciences

Looking for a Biotech Stock That's an Ideal Buyout Candidate? This Is It.

Motley Fool

Wed, 11/20/19 - 10:02 am

Acasti plays catch-up to Amarin’s Vascepa

EP Vantage

Wed, 11/20/19 - 09:56 am

AHA: Amarin's Vascepa halts progression of arterial plaque in key study

Fierce Pharma

Mon, 11/18/19 - 09:54 am

Pages